Alectinib Market Analysis by Indication (Non-Small Cell Lung Cancer (NSCLC), Other Cancers), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Patient Type (Adult Patients, Pediatric Patients), by End User (Oncology Clinics, Hospitals, Cancer Research Institutes) and by Region: Global Forecast, 2024 - 2034
- PUBLISHED ON
- 2024-04-29
- NO OF PAGES
- 191
- CATEGORY
- Healthcare & Life Sciences
Market Overview
The Alectinib market is predicted to develop at a compound annual growth rate (CAGR) of XX% from 2024 to 2034, when it is projected to reach USD XX Million, based on an average growth pattern. The market is estimated to reach a value of USD XX Million in 2024.
SOURCE: We Market Research
The U.S. Food
and Drug Administration (FDA) approved alexinatib in 2015 for the treatment of
ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients who had
progressed on crizotinib or were intolerant to it. Alectinib was first
developed by Chugai Pharmaceutical Co., Ltd. Promising clinical trial data that
showed the medication's safety profile and efficacy in this patient population
served as the foundation for approval. Alectinib functions by specifically
blocking the ALK protein, which is frequently responsible for promoting the development
of NSCLCs that are positive for ALK. As alectinib has demonstrated better
efficacy and tolerability than previous ALK inhibitors such as crizotinib, it
has gradually evolved into the standard of care for the treatment of ALK-positive
non-small cell lung cancer.
The market is driven by the exceptional effectiveness and favorable safety profile of alectinib, a targeted therapy for non-small cell lung cancer (NSCLC) that is positive for ALK. Physician preference for alelectinib has grown due to its ability to selectively target ALK-positive cancers, which has resulted in better results and longer progression-free survival. Alectinib's potential uses are further expanded by ongoing clinical trials investigating its use in various therapy situations. The market's expansion is also fueled by regulatory approvals for more widespread indications and developments in precision medicine. Alectinib's market is still growing as a top cancer therapy choice because there are more and more ALK-positive NSCLC patients looking for safe and effective treatments.
Market Scope
|
Report Attributes |
Description |
|
Market Size in 2024 |
USD XX Million |
|
Market Forecast in 2034 |
USD XX Million |
|
CAGR % 2024-2034 |
XX% |
|
Base Year |
2023 |
|
Historic Data |
2016-2022 |
|
Forecast Period |
2024-2034 |
|
Report USP
|
Production, Consumption, company share, company
heatmap, company production capacity, growth factors and more |
|
Segments Covered |
By Indication, by Distribution Channel, by Patient Type, by End
User and By Region |
|
Regional Scope |
North America, Europe, APAC, South America and
Middle East and Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic
Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia;
Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa;
Nigeria |
Alectinib Industry: Dynamics & Restrains
We Market Research: Alectinib Dashboard
Our marketing platform offers a comprehensive dashboard that provides clients with valuable insights into market trends over the years. Included below is a sample image of our dashboard, and specific PDF logins will be furnished to grant access to this insightful tool.
Alectinib Segmentation
Market- By Indication Analysis
By Indication, the Alectinib Market is Categories into Non-Small Cell Lung Cancer (NSCLC), Other Cancers. The Non-Small Cell Lung Cancer (NSCLC) segment accounts for the largest share of around 94% in 2024.
Alexib, a targeted therapy for ALK-positive
non-small cell lung cancer (NSCLC), is gaining popularity in the treatment of
NSCLC due to its improved efficacy, reduced side effects, and higher capacity
to cure brain metastases. Expanded indications and guidelines' support further
aid in its adoption since it tackles problems such as resistance mutations in
later cycles of medication.
The
following segments are part of an in-depth analysis of the global Alectinib
market:
|
Market Segments |
|
|
By Distribution
Channel |
·
Hospital Pharmacies ·
Retail Pharmacies ·
Online Pharmacies |
|
Patient Type |
·
Adult Patients ·
Pediatric Patients |
|
By End
User |
·
Oncology Clinics ·
Hospitals ·
Cancer Research Institutes |
Alectinib Industry: Regional Analysis
North America Market Forecast
North America dominate the Alectinib Market with the highest revenue generating market with share of more than 49%. North America dominates the Alectinib market because of its high healthcare spending, well-established treatment protocols, and broad use of targeted medicines like Alectinib, this area presently controls the majority of the global Alectinib market.
Europe Market Statistics
Europe is the
second largest region in Alectinib market. The European alexib market is
expanding due to a number of factors, including regulatory approvals, favorable
reimbursement policies, and growing awareness of targeted medications.
Alliances between the healthcare provider and industry, as well as mounting
clinical evidence of alelectinib's effectiveness, are driving its adoption and
facilitating patient access.
Asia Pacific Market Forecasts
Asia Pacific is
expected to be the fastest-growing regional segment of the Alectinib market
during the forecast period. The Asia-Pacific market for alexib is expanding
quickly due to a large and growing patient population with non-small cell lung
cancer (NSCLC), increased access to cutting-edge treatments, and rising
healthcare expenditures. Market dynamics are influenced by regional differences
in healthcare infrastructure, whereas regulatory approvals and clinical studies
are the primary drivers of awareness and acceptance.
Key Market Players:
Roche
1.
Global
Alectinib Market Introduction and Market Overview
1.1. Objectives of the Study
1.2. Global Alectinib Market Scope
and Market Estimation
1.2.1. Global Alectinib Overall Market
Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2034)
1.2.2. Global Alectinib Market Revenue
Share (%) and Growth Rate (Y-o-Y) from 2019 - 2034
1.3. Market Segmentation
1.3.1. Component of Global Alectinib
Market
1.3.2. Technology of Global Alectinib
Market
1.3.3. Patient Type of Global Alectinib
Market
1.3.4. Region of Global Alectinib
Market
2.
Executive Summary
2.1. Global Alectinib Market Industry Trends under COVID-19 Outbreak
2.1.1. Global COVID-19 Status Overview
2.1.2. Influence of COVID-19 Outbreak
on Global Alectinib Market
Industry Development
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Limitations
2.2.3. Opportunities
2.2.4. Impact Analysis of Drivers and Restraints
2.3. Pricing Trends Analysis &
Average Selling Prices (ASPs)
2.4. Key Mergers & Acquisitions,
Expansions, JVs, Funding / VCs, etc.
2.5. Porter’s Five Forces Analysis
2.5.1. Bargaining Power of Suppliers
2.5.2. Bargaining Power of Buyers
2.5.3. Threat of Substitutes
2.5.4. Threat of New Entrants
2.5.5. Competitive Rivalry
2.6. Value Chain / Ecosystem Analysis
2.7. Russia-Ukraine War Impacts
Analysis
2.8. Economic Downturn Analysis
2.9. Market Investment Opportunity
Analysis (Top Investment Pockets), By Segments & By Region
3.
Global Alectinib Market Estimates & Historical Trend Analysis (2019 -
2023)
4.
Global Alectinib Market Estimates & Forecast Trend Analysis, by
INDICATION
4.1. Global Alectinib Market Revenue
(US$ Mn) Estimates and Forecasts, by INDICATION, 2019 to 2034
4.1.1. Non-Small Cell Lung Cancer
(NSCLC
4.1.2. Other Cancers
5.
Global Alectinib Market Estimates & Forecast Trend Analysis, by
Distribution Channel
5.1. Global Alectinib Market Revenue
(US$ Mn) Estimates and Forecasts, by Distribution Channel, 2019 to 2034
5.1.1. Hospital Pharmacies
5.1.2. Retail Pharmacies
5.1.3. Online Pharmacies
6.
Global Alectinib Market Estimates & Forecast Trend Analysis, by
Patient Type
6.1. Global Alectinib Market Revenue
(US$ Mn) Estimates and Forecasts, by Patient Type, 2019 to 2034
6.1.1. Adult Patients
6.1.2. Pediatric Patients
7.
Global Alectinib Market Estimates & Forecast Trend Analysis, by
END USER
7.1. Global Alectinib Market Revenue
(US$ Mn) Estimates and Forecasts, by Patient Type, 2019 to 2034
7.1.1. Oncology Clinics
7.1.2. Hospitals
7.1.3. Cancer Research Institutes
8.
Global Alectinib Market Estimates & Forecast Trend Analysis,
by Region
8.1. Global Alectinib Market Revenue
(US$ Mn) Estimates and Forecasts, by Region, 2019 to 2034
8.1.1. North America
8.1.2. Europe
8.1.3. Asia Pacific
8.1.4. Middle East & Africa
8.1.5. South America
9.
North
America Alectinib Market: Estimates & Forecast Trend Analysis
9.1.
North
America Alectinib Market Assessments & Key Findings
9.1.1. North America Alectinib Market
Introduction
9.1.2. North America Alectinib Market
Size Estimates and Forecast (US$ Million) (2019 – 2034)
9.1.2.1. By INDICATION
9.1.2.2. By Distribution
Channel
9.1.2.3. By Patient Type
9.1.2.4. By END USER
9.1.2.5. By Country
9.1.2.5.1. The U.S.
9.1.2.5.2. Canada
9.1.2.5.3. Mexico
10. Europe Alectinib
Market: Estimates & Forecast Trend
Analysis
10.1. Europe Alectinib Market
Assessments & Key Findings
10.1.1. Europe Alectinib Market
Introduction
10.1.2. Europe Alectinib Market Size
Estimates and Forecast (US$ Million) (2019 – 2034)
10.1.2.1. By INDICATION
10.1.2.2. By Distribution
Channel
10.1.2.3. By Patient Type
10.1.2.4. By END USER
10.1.2.5. By Country
10.1.2.5.1. Germany
10.1.2.5.2. U.K.
10.1.2.5.3. France
10.1.2.5.4. Italy
10.1.2.5.5. Spain
10.1.2.5.6. Russia
10.1.2.5.7. Rest of Europe
11. Asia Pacific Alectinib
Market: Estimates & Forecast Trend
Analysis
11.1. Asia Pacific Market Assessments
& Key Findings
11.1.1. Asia Pacific Alectinib Market
Introduction
11.1.2. Asia Pacific Alectinib Market
Size Estimates and Forecast (US$ Million) (2019 – 2034)
11.1.2.1. By INDICATION
11.1.2.2. By Distribution
Channel
11.1.2.3. By Patient Type
11.1.2.4. By END USER
11.1.2.5. By Country
11.1.2.5.1. China
11.1.2.5.2. Japan
11.1.2.5.3. India
11.1.2.5.4. Australia
11.1.2.5.5. South Korea
11.1.2.5.6. ASEAN
11.1.2.5.7. Rest of Asia Pacific
12. Middle East & Africa Alectinib
Market: Estimates & Forecast Trend
Analysis
12.1. Middle East & Africa Market
Assessments & Key Findings
12.1.1. Middle
East & Africa Alectinib
Market Introduction
12.1.2. Middle
East & Africa Alectinib
Market Size Estimates and Forecast (US$ Million) (2019 – 2034)
12.1.2.1. By INDICATION
12.1.2.2. By Distribution
Channel
12.1.2.3. By Patient Type
12.1.2.4. By END USER
12.1.2.5. By Country
12.1.2.5.1. U.A.E.
12.1.2.5.2. Saudi Arabia
12.1.2.5.3. Egypt
12.1.2.5.4. South Africa
12.1.2.5.5. Rest of Middle East & Africa
13. South America
Alectinib Market: Estimates &
Forecast Trend Analysis
13.1. South America Market Assessments
& Key Findings
13.1.1. South America Alectinib Market
Introduction
13.1.2. South America Alectinib Market
Size Estimates and Forecast (US$ Million) (2019 – 2034)
13.1.2.1. By INDICATION
13.1.2.2. By Distribution
Channel
13.1.2.3. By Patient Type
13.1.2.4. By END USER
13.1.2.5. By Country
13.1.2.5.1. Brazil
13.1.2.5.2. Argentina
13.1.2.5.3. Colombia
13.1.2.5.4. Rest of South America
14. Competition Landscape
14.1. Global Alectinib Market
Competition Matrix & Benchmarking, by Leading Players / Innovators /
Emerging Players / New Entrants
14.2. Global Alectinib Market
Competition White Space Analysis, By Patient Type
14.3. Global Alectinib Market
Competition Heat Map Analysis, By Patient Type
14.4. Global Alectinib Market
Concentration & Company Market Shares (%) Analysis, 2022
15. Company Profiles
15.1.
Roche
15.1.1. Company Overview & Key Stats
15.1.2. Financial Performance & KPIs
15.1.3. Product Portfolio
15.1.4. Business Strategy & Recent
Developments
* Similar details would be provided
for all the players mentioned below
15.2. Others
16. Research
Methodology
16.1. External Transportations /
Databases
16.2. Internal Proprietary Database
16.3. Primary Research
16.4. Secondary Research
16.5. Assumptions
16.6. Limitations
16.7. Report FAQs
17. Research Findings & Conclusion
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
Frequently Asked Questions
What is the market size of Alectinib Market in 2024?
Alectinib Market was valued at USD XX Million in 2024.
What is the growth rate for the Alectinib Market?
Alectinib Market size will increase at approximate CAGR of XX% during the forecasted period.
Which are the top companies operating within the market?
Major company operating within the Alectinib Market is Roche.
Which region dominates the Alectinib Market?
North America dominates the market with an active share of 49%.
}})
Select a license type that suits your business needs
US $3750
Only Three Thousand Seven Hundred Fifty US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $4750
Only Four Thousand Seven Hundred Fifty US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $5750
Only Five Thousand Seven Hundred Fifty US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI